semaglutide eu Novo Nordisk wins approval for Wegovy weight-loss pill Semaglutide: price and HTA comparison

The primary endpoint was total body weight loss percentage (TBWL%) at 12 months

2- Stem cell therapies and gene therapies are moving from science fiction toward real human testing

BRI can be displayed in a visual format

Our crucial role as a pharmacy benefit manager

3/ Possible Chronic Disease Risk Reduction Cardiovascular Health: semaglutide a GLP-1-RA has shown promise of lifespan extension in obese individuals by reducing the risk of cardiovascular disease

This post hoc analysis investigated the association between major adverse cardiovascular events (MACE) and baseline kidney parameters and whether the effect of semaglutide on MACE risk was impacted by baseline kidney parameters in people with T2D at high cardiovascular risk